Please check your internet connection and try again.
## Overview
Sodium phosphate enema is a hypertonic saline solution that acts as a saline laxative by drawing water into the bowel lumen, stimulating peristalsis.
## Primary Indications
* Bowel preparation for diagnostic procedures (e.g., colonoscopy, sigmoidoscopy) or surgery.
* Relief of occasional constipation.
## Adult Dosing
* **Constipation:** Typically, one 4.5 mL unit administered rectally as needed. Do not exceed one dose in 24 hours.
* **Bowel Preparation:** Consult institutional protocol. A common regimen involves administering one 4.5 mL unit rectally the evening before the procedure. Some protocols may use multiple doses or a combination with oral sodium phosphate. Maximum dose is typically 4.5 mL per 24 hours.
## Pediatric Dosing
* **Children 2-11 years:** Consult institutional protocol. A typical dose is 2.25 mL administered rectally. Maximum dose is 2.25 mL per 24 hours.
* **Children under 2 years:** Contraindicated.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised due to potential for electrolyte disturbances.
## Contraindications
* Congenital or acquired megacolon.
* Intestinal obstruction or perforation.
* Ileus.
* Severe renal impairment (CrCl < 30 mL/min).
* Heart failure.
* Children under 2 years of age.
* Patients on medications that prolong the QT interval.
* Patients with electrolyte abnormalities or at risk for them.
* Patients unable to retain the enema.
## Adverse Effects
* **Common:** Abdominal cramping, nausea, vomiting, bloating, diarrhea.
* **Serious:** Hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia, dehydration, renal tubular damage, cardiac arrhythmias, seizures, anaphylaxis.
## Key Drug Interactions
* **Diuretics (thiazide, loop):** Increased risk of electrolyte abnormalities.
* **ACE inhibitors, ARBs, Potassium-sparing diuretics:** Increased risk of hyperkalemia.
* **Medications prolonging QT interval:** Increased risk of cardiac arrhythmias due to electrolyte shifts.
* **Calcium channel blockers:** Potential for reduced absorption and efficacy.
## Monitoring
* Electrolytes (phosphate, calcium, sodium, potassium) especially in patients with risk factors for imbalance or those receiving frequent doses.
* Renal function.
* Signs of dehydration.
* Cardiac rhythm in at-risk patients.
## Clinical Pearls
* Administer slowly and ensure the patient retains the enema for the prescribed duration (typically 5-15 minutes).
* Use with caution in elderly patients, patients with renal impairment, or those with existing electrolyte abnormalities.
* Rapid administration or excessive doses can lead to severe electrolyte disturbances and systemic toxicity.
* Consider alternative bowel preparations in patients with contraindications or increased risk of adverse effects.
This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information or other up-to-date resources.
